Eli Lilly's 10-Q: The Inventory Build That's Bigger Than the Revenue Growth
Revenue grew at a healthy clip this quarter. Inventory grew almost twice as fast. That gap is either a supply bet paying off or a warning sign, and the 10-Q has the detail to tell which.
Revenue headlines get the attention on earnings day. The balance sheet detail in the 10-Q, filed a few weeks later, is where the quieter and sometimes more important story shows up. For Eli Lilly this quarter, that story is inventory.
Inventory grew faster than sales
Total inventory on the balance sheet increased at close to double the rate of revenue growth for the quarter. For a pharmaceutical company, that gap can mean one of two very different things, and the 10-Q's notes help sort out which.
- Reading it as a supply investment. Lilly has been running capacity-constrained on its incretin franchise (the tirzepatide-based products) for several quarters, with management repeatedly flagging manufacturing capacity as the limiting factor on how fast it can meet demand. Under that read, a faster build in finished-goods and work-in-process inventory is management getting ahead of demand it already knows is coming, not overproduction.
- Reading it as a warning sign. The alternative read is that inventory is building because it isn't moving as fast as expected — meaning demand growth is decelerating from the pace management planned for when it committed to this quarter's production levels.
The notes to the financial statements break inventory into raw materials, work-in-process, and finished goods. This quarter's build was concentrated in work-in-process, which favors the supply-investment read: goods still moving through the manufacturing pipeline toward a demand base that's already been validated, rather than finished product sitting unsold in a warehouse.
Accounts receivable days ticked up too
Days sales outstanding — how long it takes Lilly to collect cash after a sale — increased modestly versus the prior quarter. On its own, a small move here doesn't mean much; quarter-to-quarter noise in receivables is normal. Paired with the inventory build, it's worth watching for a second consecutive quarter before drawing a conclusion. One quarter of both metrics moving together is coincidence until it happens twice.
R&D spend as a share of revenue held steady
Research and development expense grew roughly in line with revenue, keeping R&D intensity — R&D as a percentage of sales — flat versus the prior year. For a company mid-cycle on a major franchise launch, holding that ratio steady while the top line grows means the pipeline investment isn't being starved to fund the commercial ramp. That's a detail that would be easy to miss in the income statement alone, since both numbers are growing — it only shows up when you look at the ratio.
What we're watching next quarter
The inventory-to-sales ratio is the number to track going into the next filing. If it keeps widening for a third straight quarter, that shifts the read from "building ahead of demand" toward "demand not keeping pace with production." One more data point either resolves the question or turns it into a real concern.
Built from Eli Lilly's Q1 10-Q, including the notes to the financial statements and segment detail. Get quarter-over-quarter balance sheet shifts flagged for your own holdings at app.getrumi.app.